2024-515836-61-00招募中1 期
Combination of ALpelisib and Trametinib in progressive REfractory Meningiomas
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 35
- 试验地点
- 4
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
Thomas Graillon
Scientific
Centre Hospitalier Regional De Marseille
研究点 (4)
Loading locations...
相似试验
进行中（未招募）
1 期
Combination of ALpelisib and Trametinib in progressive REfractory MeningiomasCTIS2024-515836-61-00Centre Hospitalier Regional De Marseille28
招募中
2 期
Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat CancerOropharyngeal CancerNCT07290621University of Chicago30
招募中
2 期
Pembrolizumab in combination with lenvatinib in patients with recurrent, persistent, metastatic or locally advanced vulvar cancer not amenable to curative surgery or radiotherapy (PIERCE)2024-515646-16-00AGO Research GmbH42
招募中
2 期
Study of axitinib +/- pembrolizumab in first line treatment for patients with locally advanced or metastatic papillary renal cell carcinoma (PRCC)2024-513986-38-00Centre Leon Berard72
已完成
2 期
Phase II, Open-Label Study of preliminary efficacy of Sitravatinib in Combination with Tislelizumab in Patients with Metastatic Uveal Melanoma with liver metastases.2024-519451-29-00Grupo Espanol Multidisciplinar De Melanoma16